The Rails Ahead: Bernstein's Fresh Look at Canadian National, and What It Means for the Journey

The Market's Crystal Ball: What Brokerages Are Really Seeing in Cross Country Healthcare

The Shifting Sands of Ad Tech: Barclays Takes a Closer Look at DoubleVerify's Horizon

The Luxury Beat: Why Wall Street Is Betting Big on Tapestry's Future

Unpacking Monster's Brew: What Wall Street Really Thinks of the Energy Drink Titan's Future

Cirrus Logic's Big Leap: Why Benchmark Just Set a Bold New Price Target

The Latest Pour: Why Wall Street Is Tapping Into Molson Coors' Future

The Shifting Tides of Retail: JPMorgan's Latest Take on Newell Brands

The Alphabet Ascent: Why Bank of America Just Boosted Its Bet on Google's Future

Truist Ignites Excitement for Rapport Therapeutics (RAPP) with New 'Buy' Rating and $21 Price Target

Cybersecurity Shifts: CrowdStrike Faces Price Adjustments, Verint Acquires Teneo, and Netskope Nears IPO